Efficacy and Safety of Balloon Kyphoplasty for Pathological Vertebral Fractures in Patients with Hematological Malignancies in Our Institution

por Okada, Keigo, Fujiwara, Hiroki, Arimatsu, Tomoyuki, Motomura, Yotaro, Kato, Tsuyoshi, Takezako, Naoki, Kumagai, Takashi
Publicado 2020

Gene Expression Profile Signature of Aggressive Waldenström Macroglobulinemia with Chromosome 6q Deletion

por Sekiguchi, Naohiro, Nomoto, Junko, Nagata, Akihisa, Kiyota, Masahiro, Fukuda, Ichiro, Yamada, Kazuaki, Takezako, Naoki, Kobayashi, Yukio
Publicado 2018

Eight‐color multiparameter flow cytometry (EuroFlow‐NGF) is as sensitive as next‐generation sequencing in detecting minimal/measurable residual disease in autografts of patients wi...

por Urushihara, Ryota, Takezako, Naoki, Yoroidaka, Takeshi, Yamashita, Takeshi, Murata, Ryoichi, Satou, Kenji, Nakao, Shinji, Takamatsu, Hiroyuki
Publicado 2023

Clinical Features of Disseminated Intravascular Coagulation According to the French-American-British Classification in Patients With Acute Leukemia and Thrombomodulin Alfa Treatmen...

por Yoshinobu, Seki, Honda, Goichi, Kawano, Noriaki, Uchiyama, Toshimasa, Kawasugi, Kazuo, Madoiwa, Seiji, Takezako, Naoki, Takayuki, Ikezoe, Wada, Hideo
Publicado 2021

Pomalidomide‐bortezomib‐dexamethasone in relapsed or refractory multiple myeloma: Japanese subset analysis of OPTIMISMM

por Sunami, Kazutaka, Matsue, Kosei, Suzuki, Kenshi, Takezako, Naoki, Shinagawa, Atsushi, Sakurai, Sanae, Tamakoshi, Hiromi, Biyukov, Tsvetan, Peluso, Teresa, Richardson, Paul
Publicado 2020

Efficacy and Safety of Ixazomib Plus Lenalidomide and Dexamethasone Following Injectable PI-Based Therapy in Relapsed/Refractory Multiple Myeloma

por Abe, Yu, Sasaki, Makoto, Takezako, Naoki, Ito, Shigeki, Suzuki, Kazuhito, Handa, Hiroshi, Chou, Takaaki, Yoshida, Takahiro, Mori, Ikuo, Shinozaki, Tomohiro, Suzuki, Kenshi
Publicado 2023

Correction to: Efficacy and safety of ixazomib plus lenalidomide and dexamethasone following injectable pi‑based therapy in relapsed/refractory multiple myeloma

por Abe, Yu, Sasaki, Makoto, Takezako, Naoki, Ito, Shigeki, Suzuki, Kazuhito, Handa, Hiroshi, Chou, Takaaki, Yoshida, Takahiro, Mori, Ikuo, Shinozaki, Tomohiro, Suzuki, Kenshi
Publicado 2023

Impact of rituximab and half-dose CHOP as primary therapy for untreated symptomatic Waldenström Macroglobulinemia: review of a combined regimen of rituximab with an alkylating agen...

por Sekiguchi, Naohiro, Hamano, Airi, Kitagawa, Tomoko, Kurihara, Yuya, Ito, Kenichi, Kurimoto, Miwa, Watanabe, Kozo, Hirano, Kazuhiko, Noto, Satoshi, Yamada, Kazuaki, Takezako, Naoki
Publicado 2018

Analysis of the association between resolution of disseminated intravascular coagulation (DIC) and treatment outcomes in post-marketing surveillance of thrombomodulin alpha for DIC...

por Kawano, Noriaki, Wada, Hideo, Uchiyama, Toshimasa, Kawasugi, Kazuo, Madoiwa, Seiji, Takezako, Naoki, Suzuki, Kei, Seki, Yoshinobu, Ikezoe, Takayuki, Hattori, Tsuyoshi, Okamoto, Kohji
Publicado 2020

Carfilzomib, lenalidomide and dexamethasone in patients with heavily pretreated multiple myeloma: A phase 1 study in Japan

por Suzuki, Kenshi, Ri, Masaki, Chou, Takaaki, Sugiura, Isamu, Takezako, Naoki, Sunami, Kazutaka, Ishida, Tadao, Izumi, Tohru, Ozaki, Shuji, Shumiya, Yoshihisa, Ota, Kenji, Iida, Shinsuke
Publicado 2017

Severe Antithrombin Deficiency May be Associated With a High Risk of Pathological Progression of DIC With Suppressed Fibrinolysis

por Wada, Hideo, Honda, Goichi, Kawano, Noriaki, Uchiyama, Toshimasa, Kawasugi, Kazuo, Madoiwa, Seiji, Takezako, Naoki, Suzuki, Kei, Seki, Yoshinobu, Ikezoe, Takayuki, Iba, Toshiaki, Okamoto, Kohji
Publicado 2020

Once-weekly vs. twice-weekly carfilzomib dosing in a subgroup of Japanese relapsed and refractory multiple myeloma patients from a randomized phase 3 trial (A.R.R.O.W.) and compari...

por Takezako, Naoki, Shibayama, Hirohiko, Handa, Hiroshi, Hagiwara, Shotaro, Ozaki, Shuji, Suzuki, Kenshi, Kosugi, Hiroshi, Ri, Masaki, Sugiura, Isamu, Choi, Ilseung, Miyamoto, Toshihiro, Iida, Shinsuke
Publicado 2020

Hypofibrinogenemia is associated with a high degree of risk in infectious diseases: a post-hoc analysis of post-marketing surveillance of patients with disseminated intravascular c...

por Kawasugi, Kazuo, Wada, Hideo, Honda, Goichi, Kawano, Noriaki, Uchiyama, Toshimasa, Madoiwa, Seiji, Takezako, Naoki, Suzuki, Kei, Seki, Yoshinobu, Ikezoe, Takayuki, Iba, Toshiaki, Okamoto, Kohji
Publicado 2021

Sepsis-Associated DIC with Decreased Levels of Antithrombin and Fibrinogen is the Target for Combination Therapy with Thrombomodulin Alfa and Antithrombin

por Wada, Hideo, Kawasugi, Kazuo, Honda, Goichi, Kawano, Noriaki, Uchiyama, Toshimasa, Madoiwa, Seiji, Takezako, Naoki, Suzuki, Kei, Seki, Yoshinobu, Ikezoe, Takayuki, Iba, Toshiaki, Okamoto, Kohji
Publicado 2023

Alternating bortezomib-dexamethasone and lenalidomide-dexamethasone in patients with newly diagnosed multiple myeloma aged over 75 years

por Yokoyama, Akihiro, Kada, Akiko, Kagoo, Toshiya, Hidaka, Michihiro, Iida, Hiroatsu, Miyata, Yasuhiko, Saito, Akiko M., Sawamura, Morio, Komeno, Takuya, Sunami, Kazutaka, Takezako, Naoki, Nagai, Hirokazu
Publicado 2022

Daratumumab, lenalidomide, and dexamethasone in East Asian patients with relapsed or refractory multiple myeloma: subgroup analyses of the phase 3 POLLUX study

por Suzuki, Kenshi, Dimopoulos, Meletios A., Takezako, Naoki, Okamoto, Shinichiro, Shinagawa, Atsushi, Matsumoto, Morio, Kosugi, Hiroshi, Yoon, Sung-Soo, Huang, Shang-Yi, Qin, Xiang, Qi, Ming, Iida, Shinsuke
Publicado 2018

Dasatinib rapidly induces deep molecular response in chronic-phase chronic myeloid leukemia patients who achieved major molecular response with detectable levels of BCR-ABL1 transc...

por Shiseki, Masayuki, Yoshida, Chikashi, Takezako, Naoki, Ohwada, Akira, Kumagai, Takashi, Nishiwaki, Kaichi, Horikoshi, Akira, Fukuda, Tetsuya, Takano, Hina, Kouzai, Yasuji, Tanaka, Junji, Morita, Satoshi, Sakamoto, Junichi, Sakamaki, Hisashi, Inokuchi, Koiti
Publicado 2017

Dasatinib cessation after deep molecular response exceeding 2 years and natural killer cell transition during dasatinib consolidation

por Kumagai, Takashi, Nakaseko, Chiaki, Nishiwaki, Kaichi, Yoshida, Chikashi, Ohashi, Kazuteru, Takezako, Naoki, Takano, Hina, Kouzai, Yasuji, Murase, Tadashi, Matsue, Kosei, Morita, Satoshi, Sakamoto, Junichi, Wakita, Hisashi, Sakamaki, Hisashi, Inokuchi, Koiti
Publicado 2017

Silent NK/T cell reactions to dasatinib during sustained deep molecular response before cessation are associated with longer treatment‐free remission

por Kumagai, Takashi, Nakaseko, Chiaki, Nishiwaki, Kaichi, Yoshida, Chikashi, Ohashi, Kazuteru, Takezako, Naoki, Takano, Hina, Kouzai, Yasuji, Murase, Tadashi, Matsue, Kosei, Morita, Satoshi, Sakamoto, Junichi, Wakita, Hisashi, Sakamaki, Hisashi, Inokuchi, Koiti
Publicado 2020

Elotuzumab Plus Pomalidomide and Dexamethasone for Relapsed/Refractory Multiple Myeloma: Final Overall Survival Analysis From the Randomized Phase II ELOQUENT-3 Trial

por Dimopoulos, Meletios A., Dytfeld, Dominik, Grosicki, Sebastian, Moreau, Philippe, Takezako, Naoki, Hori, Mitsuo, Leleu, Xavier, LeBlanc, Richard, Suzuki, Kenshi, Raab, Marc S., Richardson, Paul G., Popa McKiver, Mihaela, Jou, Ying-Ming, Yao, David, Das, Prianka, San-Miguel, Jesús
Publicado 2023